当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.

Abstract：

BACKGROUND:Metastatic bladder cancer is a serious condition with a 5-year survival rate of approximately 14 %, a rate that has remained unchanged for almost three decades. Thus, there is a profound need to identify the driving mutations for these aggressive tumors to better determine appropriate treatments. Mutational analyses of clinical samples suggest that mutations in either the phosphoinositide-3 kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) or RAS/MEK/ERK pathways drive bladder cancer progression, although it remains to be tested whether the inhibition of either (or both) of these pathways can arrest PI3K/mTOR- or Ras-driven proliferation. METHODS:Herein, we used several bladder cancer cell lines to determine drug sensitivity according to genetic background and also studied mouse models of engrafted UM-UC-3 cells and patient-derived xenografts (PDXs) to test PI3K/mTOR and MEK inhibition in vivo. RESULTS:Inhibition of these pathways utilizing PF-04691502, a PI3K and mTOR inhibitor, and PD-0325901, a MEK inhibitor, slowed the tumor growth of PDX models of bladder cancer. The growth inhibitory effect of combination therapy was similar to that of the clinical maximum dose of cisplatin; mechanistically, this appeared to predominantly occur via drug-induced cytostatic growth inhibition as well as diminished vascular endothelial growth factor secretion in the tumor models. Kinase arrays of tumors harvested after treatment demonstrated activated p53 and Axl as well as STAT1 and STAT3. CONCLUSION:Taken together, these results indicate that clinically relevant doses of PF-04691502 and PD-0325901 can suppress bladder tumor growth in PDX models, thus offering additional potential treatment options by a precision medicine approach.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Cirone P,Andresen CJ,Eswaraka JR,Lappin PB,Bagi CM

doi

10.1007/s00280-014-2376-1

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

525-38

issue

3

eissn

0344-5704

issn

1432-0843

journal_volume

73

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.

    abstract：PURPOSE:There is a need to find novel oestrogen receptor (ER) ligands that antagonize oestrogen action in the reproductive tissues and would therefore have therapeutic potential in oestrogen-dependent tumours. We tested novel ER ligands in both breast and endometrial cells to profile agonism/antagonism in these oestrog...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800000259

    authors： Nuttall ME,Pendrak I,Emery JG,Nadeau DP,Fisher PW,Nicholson TA,Zhu Y,Suva LJ,Kingsbury WD,Gowen M

    更新日期：2001-05-01 00:00:00

  • The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.

    abstract：PURPOSE:The present study was designed to investigate the ability of N-[4-(5-bromo-2-pyrimidyloxy)-3-methylphenyl]-(dimemethylamino)-benzoylphenylurea (dimemethylamino benzoylphenylurea; BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cel...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0333-3

    authors： Balcer-Kubiczek EK,Attarpour M,Edelman MJ

    更新日期：2007-05-01 00:00:00

  • Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.

    abstract：:The ability of the polysulfonated antitumor drug suramin and six related polysulfonated azo dyes to inhibit the cell growth, platelet-derived growth factor (PDGF)-receptor binding, and intracellular Ca2+ signaling of Swiss 3T3 fibroblasts was studied. Some of the azo dyes were more potent inhibitors of PDGF binding th...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685552

    authors： Powis G,Seewald MJ,Melder D,Hoke M,Gratas C,Christensen TA,Chapman DE

    更新日期：1992-01-01 00:00:00

  • Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats.

    abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00256721

    authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

    更新日期：1983-01-01 00:00:00

  • Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.

    abstract：BACKGROUND:The objective of this study was to evaluate the efficacy and safety of concurrent immune checkpoint inhibitor therapy and radiotherapy (immunoradiotherapy) in patients with metastatic melanoma after progression on nivolumab. PATIENTS AND METHODS:A retrospective review was performed on 16 consecutive patient...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3557-0

    authors： Nomura M,Otsuka A,Yoshimura M,Nonomura Y,Kaku Y,Matsumoto S,Muto M

    更新日期：2018-05-01 00:00:00

  • Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

    abstract：PURPOSE:This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis(®)) 3 mg/m(2) 1 h every 3-week intravenous infusion in patients with advanced and/or metastatic urothelial carcinoma progressing after first-line platinum-based chemotherapy. METH...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2419-7

    authors： Castellano DE,Bellmunt J,Maroto JP,Font-Pous A,Morales-Barrera R,Ghanem I,Suarez C,Martín Lorente C,Etxaniz O,Capdevila L,Coronado C,Alfaro V,Siguero M,Fernández-Teruel C,Carles J

    更新日期：2014-04-01 00:00:00

  • Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.

    abstract：PURPOSE:Although cisplatin is an important agent in non-small-cell lung cancer (NSCLC), de novo resistance is common and acquired resistance emerges rapidly during therapy. Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression. While...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800100293

    authors： Lara PN Jr,Gandara DR,Longmate J,Gumerlock PH,Lau DH,Edelman MJ,Gandour-Edwards R,Mack PC,Israel V,Raschko J,Frankel P,Perez EA,Lenz HJ,Doroshow JH

    更新日期：2001-07-01 00:00:00

  • Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.

    abstract：OBJECTIVE:To study the pharmacokinetics of neamine in rats and to evaluate its anti-cervical cancer activity. METHODS:The plasma level of neamine was determined by HPLC-ELSD. Pharmacokinetic parameters were calculated using DAS 2.0 software. Tissue microarray analysis was conducted to examine angiogenin (ANG) expressi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2658-7

    authors： Liu Y,Zhang X,An S,Wu Y,Hu G,Wu Y

    更新日期：2015-03-01 00:00:00

  • Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.

    abstract：PURPOSE:To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on the pharmacokinetics and pharmacodynamics of the new morpholino anthracycline drug MX2. METHODS:A total of 25 patients with advanced malignant disease participated in a dose-escalation study in the first cycle of treatment given i.v....

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050761

    authors： Morgan DJ,Hill JS,Clarke K,Stylli SS,Park SJ,Cebon J,Basser RL,Kaye AH,Geldard H,Maher DW,Green MD

    更新日期：1998-01-01 00:00:00

  • Antitumor activity of interleukin 12 in preclinical models.

    abstract：:Interleukin 12 (IL-12) is a heterodimeric cytokine with a number of biological effects that are consistent with its potential role as an antitumor agent. The antimetastatic and antitumor activities of IL-12 have been demonstrated in a number of murine tumor models. Both the inhibition of established experimental pulmo...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s002800051031

    authors： Brunda MJ,Luistro L,Rumennik L,Wright RB,Dvorozniak M,Aglione A,Wigginton JM,Wiltrout RH,Hendrzak JA,Palleroni AV

    更新日期：1996-01-01 00:00:00

  • Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13.

    abstract：:The effects of anticalmodulin agents, namely trifluoperazine (TFP) and two naphthalene sulfonamide derivatives (W-7 and W-13), were tested on the growth of a human breast cancer cell line (MDA-MB-231) using a soft agar clonogenic assay. The results of this in vitro study reveal that TFP, W-7, and W-13 had the ability ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00254251

    authors： Wei JW,Hickie RA,Klaassen DJ

    更新日期：1983-01-01 00:00:00

  • Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine.

    abstract：:Glutathione (GSH) transferases (GST), a family of detoxification enzyme proteins, are suggested to play an important role in tumor cell resistance to melphalan. The GST-activity inhibitor ethacrynic acid has been shown to increase the antitumor activity of melphalan in vitro as well as in vivo. In this study we determ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685726

    authors： Gupta V,Jani JP,Jacobs S,Levitt M,Fields L,Awasthi S,Xu BH,Sreevardhan M,Awasthi YC,Singh SV

    更新日期：1995-01-01 00:00:00

  • Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection.

    abstract：:A total of 135 patients with hepatocellular carcinoma (HCC) were treated by intra-arterial injection of an Adriamycin/mitomycin C oil (lipiodol) suspension (ADMOS) alone or of ADMOS plus cis-diammine-dichloroplatinum (CDDP). In all, 59 patients were treated with ADMOS alone and 76 were treated with ADMOS plus CDDP. A ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00687108

    authors： Ikeda K,Inoue H,Yano T,Kobayashi H,Nakajo M

    更新日期：1992-01-01 00:00:00

  • A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.

    abstract：PURPOSE:Fruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors (1, 2 and 3). This study was conducted to investigate the metabolism, excretion, and pharmacokinetics of HMPL-013 after a single oral dose to healthy Chinese men....

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3394-6

    authors： Zhou S,Shao F,Xu Z,Wang L,Jin K,Xie L,Chen J,Liu Y,Zhang H,Ou N

    更新日期：2017-09-01 00:00:00

  • The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.

    abstract：PURPOSE:We reported the first case of phenytoin intoxication due to the concomitant use of phenytoin and TS-1, together with a review of the literature regarding the occurrence of phenytoin intoxication due to the concomitant use of phenytoin and fluoropyrimidine antitumor drugs such as fluorouracil (5-FU) and tegafur ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0621-6

    authors： Tsuda A,Fujiyama J,Miki A,Hori S,Ohtani H,Sawada Y

    更新日期：2008-08-01 00:00:00

  • Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

    abstract：PURPOSE:Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3625-5

    authors： Thomas F,Veal GJ,El Balkhi S,Lafont T,Picard N,Brugières L,Chatelut E,Piguet C

    更新日期：2018-08-01 00:00:00

  • Population pharmacokinetic model of PI-88, a heparanase inhibitor.

    abstract：PURPOSE:The aim of this study was to investigate typical population pharmacokinetic (PK) parameters, potential covariates, and interindividual and residual variabilities of PI-88, a heparanase endoglycosidase enzyme inhibitor being developed for the treatment of cancer. METHODS:A population PK model of PI-88 was devel...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-1080-z

    authors： Hudachek SF,Eckhardt SG,Hicks B,Gustafson DL

    更新日期：2010-03-01 00:00:00

  • Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients.

    abstract：PURPOSE:The aim of this study was to determine the usefulness of receptor occupancy theory-based analysis using pharmacokinetic and pharmacodynamic parameters for predicting the average receptor occupancy (PhiB) in humans of each of five 5-HT3 antagonists administered at standard doses. METHODS:The relationship betwee...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0798-x

    authors： Yamada Y,Sugiura M,Higo K,Ozeki T,Takayanagi R,Okuyama K,Yamamoto K,Satoh H,Sawada Y,Iga T

    更新日期：2004-08-01 00:00:00

  • Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.

    abstract：BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2358-8

    authors： Philips KB,Kurtoglu M,Leung HJ,Liu H,Gao N,Lehrman MA,Murray TG,Lampidis TJ

    更新日期：2014-02-01 00:00:00

  • Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.

    abstract：PURPOSE:The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. PATIENTS AND METHODS:From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0505-9

    authors： Choi HJ,Cho BC,Shin SJ,Cheon SH,Jung JY,Chang J,Kim SK,Sohn JH,Kim JH

    更新日期：2008-02-01 00:00:00

  • In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.

    abstract：PURPOSE:Artemisinins are now established drugs for treatment of malaria. These agents have been shown to possess impressive anti-cancer properties. We have investigated the role of artemisone (ATM), a novel derivative of artemisinin (ART) in a cancer setting both alone and in combination with established chemotherapeut...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1355-4

    authors： Gravett AM,Liu WM,Krishna S,Chan WC,Haynes RK,Wilson NL,Dalgleish AG

    更新日期：2011-03-01 00:00:00

  • A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.

    abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2760-5

    authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

    更新日期：2015-09-01 00:00:00

  • Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

    abstract：:We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0554-0

    authors： Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

    更新日期：2008-05-01 00:00:00

  • Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study.

    abstract：PURPOSE:The aim of the present study was to develop a new strategy for combined thermo-chemotherapy of cancer. For this purpose, we used ultrasound waves [1 MHz; 1 W/cm2; 10 min] in combination with a sonosensitizing nanoplatform, named ACA, made of alginate co-loaded with cisplatin and gold nanoparticles (AuNPs). MET...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03961-9

    authors： Irajirad R,Ahmadi A,Najafabad BK,Abed Z,Sheervalilou R,Khoei S,Shiran MB,Ghaznavi H,Shakeri-Zadeh A

    更新日期：2019-12-01 00:00:00

  • Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity.

    abstract：PURPOSE:P-glycoprotein is a 170-kDa plasma membrane multidrug transporter that actively exports cytotoxic substances from cells. Overexpression of P-glycoprotein by tumor cells is associated with a multidrug-resistant phenotype. Immunosuppressive agents such as cyclosporins and macrolides, have been shown to attenuate ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050960

    authors： Mealey KL,Barhoumi R,Burghardt RC,McIntyre BS,Sylvester PW,Hosick HL,Kochevar DT

    更新日期：1999-01-01 00:00:00

  • Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.

    abstract：PURPOSE:Thymidylate synthase (TS) is one of the target molecules for the antitumor effects of fluoropyrimidine drugs. The cellular thymidylate synthase level is one of the determining factors for the antitumor activity of fluoropyrimidines. TYMS, which encodes TS, has been reported to possess 28-bp tandem repeat sequen...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-1018-z

    authors： Yawata A,Kim SR,Miyajima A,Kubo T,Ishida S,Saito Y,Nakajima Y,Katori N,Matsumoto Y,Fukuoka M,Ohno Y,Ozawa S,Sawada J

    更新日期：2005-11-01 00:00:00

  • Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.

    abstract：PURPOSE:Phosphatidylinositol (PtdIns) 3-kinase is an important mediator of many cellular functions. The study of PtdIns 3-kinase has been facilitated by the existence of the potent irreversible inhibitor of p110 PtdIns 3-kinase, wortmannin. The purpose of the study was to investigate the relationship between the cell g...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800051123

    authors： Lemke LE,Paine-Murrieta GD,Taylor CW,Powis G

    更新日期：1999-01-01 00:00:00

  • Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.

    abstract：OBJECTIVES:Concurrent chemoradiotherapy (CRT) is the current standard of treatment for anal squamous carcinoma. However, local or metastatic recurrences remain significant after CRT with 5-fluorouracil (5-FU) and mitomycin C (MMC). Therefore, the present study evaluated the feasibility and efficacy of adding cisplatin ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3185-5

    authors： Lee IH,Lee SJ,Kang BW,Chae YS,Baek D,Hwang S,Kim HJ,Park SY,Park JS,Choi GS,Kim JC,Kim JG

    更新日期：2016-12-01 00:00:00

  • Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.

    abstract：PURPOSE:The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients'...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1361-6

    authors： Heshe D,Hoogestraat S,Brauckmann C,Karst U,Boos J,Lanvers-Kaminsky C

    更新日期：2011-03-01 00:00:00

  • Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1.

    abstract：PURPOSE:Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed cancers worldwide with significantly high prevalence in Southern China. Chemoprevention of cancer with alkylating agent compounds could potentially reverse, suppress, or prevent cancer progression. Cisplatin (CIS) is an antineoplastic or cytot...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3536-5

    authors： Yin P,Song G,Jiang Z

    更新日期：2018-05-01 00:00:00